HBI Deals+Insights / M&A/IPOs
French private equity firm ArchiMed is taking Nasdaq-listed commercial biopharma firm Esperion Therapeutics private for ~$1 billion. Esperion develops cardiometabolic and rare/orphan disease therapies.





